Antibiotic resistance in Staphylococcus aureus colonising the intestines of Swedish infants

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
E LindbergA E Wold

Abstract

Staphylococcus aureus has become a frequent coloniser of the intestinal tract of infants, but the health effects of such colonisation are not clear. In this study, the antibiotic resistance patterns of 116 S. aureus strains from the commensal intestinal microflora were determined. The strains were obtained from 81 Swedish infants who had been followed with regular stool samples and registration of antibiotic usage during their first year of life. The faecal population levels of the individual strains and the duration of their persistence in the microflora had been determined previously. The prevalence of antibiotic resistance among the 116 strains was modest: methicillin, 0%; penicillin G, 78%; erythromycin A, 3%; tetracycline, 2%; clindamycin, 0.9%; and fusidic acid, 0.9%. Colonisation by antibiotic-resistant strains was unrelated to antibiotic consumption by individual infants. Antibiotic-resistant strains were as capable of persisting in the intestinal microflora and reaching high faecal population levels as fully susceptible strains. No strain lost or acquired resistance during the colonisation period. Thus, antibiotic-resistant strains of S. aureus seem to be as fit for competition in the large bowel microflora as suscepti...Continue Reading

References

Feb 1, 1991·The Journal of Antimicrobial Chemotherapy·D F Brown, L Brown
Jul 1, 1994·Journal of Clinical Microbiology·D J GehaD H Persing
Nov 1, 1996·Antimicrobial Agents and Chemotherapy·J SutcliffeL Wondrack
Jan 4, 2001·International Journal of Antimicrobial Agents·D M Livermore
May 1, 2001·The Journal of Antimicrobial Chemotherapy·M R MillarUNKNOWN ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood
Jun 19, 2001·Lancet·O CarsA Melander
May 25, 2002·Emerging Infectious Diseases·Saara SalmenlinnaJaana Vuopio-Varkila
Dec 13, 2002·Scandinavian Journal of Infectious Diseases·A OsterlundUNKNOWN Swedish Study Group on Fusidic Acid-resistant Staphylococcus aureus
Apr 4, 2003·The New England Journal of Medicine·Soju ChangUNKNOWN Vancomycin-Resistant Staphylococcus aureus Investigative Team
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Fred C TenoverBülent Bozdogan
Feb 10, 2004·Journal of Clinical Microbiology·Erika LindbergAgnes E Wold

❮ Previous
Next ❯

Citations

Aug 21, 2009·Archivum Immunologiae Et Therapiae Experimentalis·Marco Cesar Cunegundes GuimarãesMarcos Fernando de Rezende Matta
Jan 31, 2013·Pediatrics International : Official Journal of the Japan Pediatric Society·Asem A ShehabiKarsten Becker
Aug 1, 2006·Biological Psychiatry·Sergueï O FetissovTomas Hökfelt
Jun 22, 2005·International Journal of Antimicrobial Agents·Susan F PlummerJohn Hunter
Jun 1, 2016·Frontiers in Microbiology·Shantelle Claassen-WeitzMamadou Kaba
May 3, 2021·Antimicrobial Resistance and Infection Control·Bahareh HajikhaniMasoud Dadashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.